<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:media="http://search.yahoo.com/mrss/" >

<channel>
	<title>ABT &#8211; Stock Earnings</title>
	<atom:link href="https://cms.stocksearning.com/tag/abt/feed/" rel="self" type="application/rss+xml" />
	<link>https://cms.stocksearning.com</link>
	<description>Empowering Investors and Traders</description>
	<lastBuildDate>Wed, 07 Oct 2026 20:04:20 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.4</generator>

<image>
	<url>https://cms.stocksearning.com/wp-content/uploads/2025/10/cropped-cropped-SE_lovo_bimi-32x32.jpg</url>
	<title>ABT &#8211; Stock Earnings</title>
	<link>https://cms.stocksearning.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>3 Income ETFs to Help Build a More Resilient Portfolio in a Crazed Market</title>
		<link>https://cms.stocksearning.com/2026/10/3-etfs-for-resilient-portfolio/</link>
					<comments>https://cms.stocksearning.com/2026/10/3-etfs-for-resilient-portfolio/#respond</comments>
		
		<dc:creator><![CDATA[Ian Cooper]]></dc:creator>
		<pubDate>Wed, 07 Oct 2026 20:00:00 +0000</pubDate>
				<category><![CDATA[Evergreen]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AFL]]></category>
		<category><![CDATA[BRK.B]]></category>
		<category><![CDATA[CAT]]></category>
		<category><![CDATA[CVX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[KO]]></category>
		<category><![CDATA[NOBL]]></category>
		<category><![CDATA[PEP]]></category>
		<category><![CDATA[PG]]></category>
		<category><![CDATA[QCOM]]></category>
		<category><![CDATA[SCHD]]></category>
		<category><![CDATA[SCHV]]></category>
		<category><![CDATA[TXN]]></category>
		<category><![CDATA[wmt]]></category>
		<category><![CDATA[XOM]]></category>
		<guid isPermaLink="false">https://cms.stocksearning.com/?p=8779</guid>

					<description><![CDATA[Investors looking for alternatives to the  hottest growth stocks can consider income ETFs that combine dividends, value exposure, and relatively low costs.]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">Dividend ETFs and low-cost value funds can help investors build a more resilient portfolio while collecting income along the way. For investors looking beyond the market’s hottest growth stocks, <strong>ProShares S&amp;P 500 Dividend Aristocrats ETF (BATS: NOBL)</strong>, <strong>Schwab U.S. Large-Cap Value ETF (NYSEARCA: SCHV)</strong>, and <strong>Schwab U.S. Dividend Equity ETF (NYSEARCA: SCHD)</strong> offer three approaches worth understanding. </p>



<div class="wp-block-rank-math-toc-block" id="rank-math-toc"><h2>Table of Contents</h2><nav><ul><li><a href="#pro-shares-s-p-500-dividend-aristocrats-etf">ProShares S&amp;P 500 Dividend Aristocrats ETF </a></li><li><a href="#schwab-u-s-large-cap-value-etf">Schwab U.S. Large-Cap Value ETF </a></li><li><a href="#schwab-u-s-dividend-equity-etf">Schwab U.S. Dividend Equity ETF </a></li><li><a href="#build-a-portfolio-you-can-stick-with">Build a Portfolio You Can Stick With</a></li></ul></nav></div>



<p class="wp-block-paragraph">The goal is to build a portfolio you can comfortably hold through difficult markets. That’s where these three funds come in.</p>



<h2 id="pro-shares-s-p-500-dividend-aristocrats-etf" class="wp-block-heading">ProShares S&amp;P 500 Dividend Aristocrats ETF&nbsp;</h2>



<p class="wp-block-paragraph">For investors who want exposure to dividend growers without choosing individual stocks, NOBL offers a straightforward approach. The fund <a href="https://www.proshares.com/globalassets/proshares/fact-sheet/prosharesfactsheetnobl.pdf" target="_blank" rel="noopener">follows the S&amp;P 500 Dividend Aristocrats Index</a>. Its expense ratio remains 0.35%, or about $35 annually for every $10,000 invested.&nbsp;</p>



<p class="wp-block-paragraph">ProShares reported a 30-day SEC yield of 2.09% and a trailing 12-month yield of 2.01%, both as of August 31, 2026. Some of its top holdings to date include <strong><a href="https://stocksearning.com/stocks/WMT/earnings-date">Walmart (NASDAQ: WMT)</a></strong>, <strong><a href="https://stocksearning.com/stocks/CAT/earnings-date">Caterpillar (NYSE: CAT)</a></strong>, <strong><a href="https://stocksearning.com/stocks/ABT/earnings-date">Abbott Laboratories (NYSE: ABT)</a></strong>, <strong><a href="https://stocksearning.com/stocks/AFL/earnings-date">Aflac (NYSE: AFL)</a></strong>, and <strong><a href="https://stocksearning.com/stocks/PEP/earnings-date">PepsiCo (NASDAQ: PEP)</a></strong>, among others. That gives investors exposure to businesses across several industries through one purchase.</p>



<p class="wp-block-paragraph">The appeal is easy to understand: These companies have demonstrated a willingness and ability to increase shareholder payments over time.</p>



<figure class="wp-block-image size-large"><img fetchpriority="high" decoding="async" width="600" height="315" data-source="article-image" src="https://cms.stocksearning.com/wp-content/uploads/2026/10/NOBL_2026-10-07_14-17-36-600x315.png" alt="etf - StockEarnings" class="wp-image-8806" srcset="https://cms.stocksearning.com/wp-content/uploads/2026/10/NOBL_2026-10-07_14-17-36-600x315.png 600w, https://cms.stocksearning.com/wp-content/uploads/2026/10/NOBL_2026-10-07_14-17-36-300x158.png 300w, https://cms.stocksearning.com/wp-content/uploads/2026/10/NOBL_2026-10-07_14-17-36-768x404.png 768w, https://cms.stocksearning.com/wp-content/uploads/2026/10/NOBL_2026-10-07_14-17-36.png 1438w" sizes="(max-width: 600px) 100vw, 600px" /></figure>



<h2 id="schwab-u-s-large-cap-value-etf" class="wp-block-heading">Schwab U.S. Large-Cap Value ETF&nbsp;</h2>



<p class="wp-block-paragraph">SCHV takes a broader approach, giving investors exposure to large U.S. companies classified as value stocks. It tracks the Dow Jones U.S. Large-Cap Value Total Stock Market Index and charges just 0.04% annually. That works out to about $4 per year on a $10,000 investment. Its 30-day SEC yield was 1.84% as of October 5, 2026.</p>



<p class="wp-block-paragraph">Some of its top holdings include <strong>Berkshire Hathaway (NYSE: BRK-B)</strong>, <strong><a href="https://stocksearning.com/stocks/JPM/earnings-date">JPMorgan Chase (NYSE: JPM)</a></strong>, <a href="https://stocksearning.com/stocks/XOM/earnings-date"><strong>Exxon Mobil (NYSE: XOM</strong>)</a>, and <strong><a href="https://stocksearning.com/stocks/JNJ/earnings-date">Johnson &amp; Johnson (NYSE: JNJ)</a></strong>. SCHV can appeal to investors who want broad value exposure at a very low cost.</p>



<figure class="wp-block-image size-large"><img decoding="async" width="600" height="315" data-source="article-image" src="https://cms.stocksearning.com/wp-content/uploads/2026/10/SCHV_2026-10-07_14-18-07-600x315.png" alt="etf - StockEarnings" class="wp-image-8807" srcset="https://cms.stocksearning.com/wp-content/uploads/2026/10/SCHV_2026-10-07_14-18-07-600x315.png 600w, https://cms.stocksearning.com/wp-content/uploads/2026/10/SCHV_2026-10-07_14-18-07-300x158.png 300w, https://cms.stocksearning.com/wp-content/uploads/2026/10/SCHV_2026-10-07_14-18-07-768x403.png 768w, https://cms.stocksearning.com/wp-content/uploads/2026/10/SCHV_2026-10-07_14-18-07.png 1439w" sizes="(max-width: 600px) 100vw, 600px" /></figure>



<h2 id="schwab-u-s-dividend-equity-etf" class="wp-block-heading">Schwab U.S. Dividend Equity ETF&nbsp;</h2>



<p class="wp-block-paragraph">For investors placing greater emphasis on income, SCHD offers another option.</p>



<p class="wp-block-paragraph">The fund tracks the Dow Jones U.S. Dividend 100 Index and maintains an expense ratio of 0.06%. That’s approximately $6 annually for every $10,000 invested. Its 30-day SEC yield was 3.37% as of October 5, 2026. It also has a distribution yield of 3%. Its holdings included <strong><a href="https://stocksearning.com/stocks/TXN/earnings-date">Texas Instruments (NASDAQ: TXN)</a></strong>, <strong><a href="https://stocksearning.com/stocks/QCOM/earnings-date">Qualcomm (NASDAQ: QCOM)</a>,</strong> <a href="https://stocksearning.com/stocks/PG/earnings-date"><strong>Procter &amp; Gamble (NYSE: PG</strong>)</a>, <strong><a href="https://stocksearning.com/stocks/CVX/earnings-date">Chevron (NYSE: CVX)</a></strong>, and <strong><a href="https://stocksearning.com/stocks/KO/earnings-date">Coca-Cola (NYSE: KO)</a></strong>.</p>



<p class="wp-block-paragraph">That mix gives investors access to dividend-paying businesses across technology, consumer products, energy, and other industries.</p>



<figure class="wp-block-image size-large"><img decoding="async" width="600" height="315" data-source="article-image" src="https://cms.stocksearning.com/wp-content/uploads/2026/10/SCHD_2026-10-07_14-18-39-600x315.png" alt="etf - StockEarnings" class="wp-image-8808" srcset="https://cms.stocksearning.com/wp-content/uploads/2026/10/SCHD_2026-10-07_14-18-39-600x315.png 600w, https://cms.stocksearning.com/wp-content/uploads/2026/10/SCHD_2026-10-07_14-18-39-300x158.png 300w, https://cms.stocksearning.com/wp-content/uploads/2026/10/SCHD_2026-10-07_14-18-39-768x404.png 768w, https://cms.stocksearning.com/wp-content/uploads/2026/10/SCHD_2026-10-07_14-18-39.png 1438w" sizes="(max-width: 600px) 100vw, 600px" /></figure>



<h2 id="build-a-portfolio-you-can-stick-with" class="wp-block-heading">Build a Portfolio You Can Stick With</h2>



<p class="wp-block-paragraph">Building a more resilient portfolio starts with understanding what you own and why you own it. NOBL emphasizes companies with long records of dividend increases. SCHV offers broad exposure to large value stocks at a low cost. SCHD puts greater emphasis on dividend income. Each offers a different way to approach the same goal: growing your money while collecting income along the way.</p>



<p class="wp-block-paragraph">That doesn’t mean you need all three. Their holdings can overlap, so combining them won’t necessarily provide as much additional diversification as you might expect. A better starting point is to consider what your portfolio needs. Are you looking for income to help cover expenses, dividends to reinvest, or broader exposure beyond growth stocks?</p>



<p class="wp-block-paragraph">It also helps to look beyond the yield. Fees, holdings, and the fund’s strategy all matter. An attractive payout means less if the investment takes on more risk than you’re comfortable holding through a downturn.</p>



<p class="wp-block-paragraph">These ETFs won’t eliminate market losses, but they can be useful pieces of a long-term plan. Choose investments that fit your goals, keep your expectations realistic, and give your strategy time to work. A portfolio you understand and can stick with is often more useful than one built around whatever happens to be grabbing headlines.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://cms.stocksearning.com/2026/10/3-etfs-for-resilient-portfolio/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Abbott Labs Stock Looks Ready for a Rally After a Tough Year</title>
		<link>https://cms.stocksearning.com/2026/10/abbott-labs-could-be-due-for-a-rally/</link>
					<comments>https://cms.stocksearning.com/2026/10/abbott-labs-could-be-due-for-a-rally/#respond</comments>
		
		<dc:creator><![CDATA[Joshua Enomoto]]></dc:creator>
		<pubDate>Thu, 01 Oct 2026 13:45:00 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[ABT]]></category>
		<guid isPermaLink="false">https://cms.stocksearning.com/?p=8388</guid>

					<description><![CDATA[While the pessimism surrounding Abbott Laboratories has investors shaken up, options traders may find ABT stock compelling.]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">You don’t need to find many excuses to avoid <a href="https://stocksearning.com/stocks/ABT/earnings-date"><strong>Abbott Laboratories</strong> <strong>(NYSE:ABT)</strong></a>. Despite its powerhouse label in the healthcare segment, ABT stock simply hasn’t lived up to the billing. Since the start of the year, the ticker is down more than 19%. Recent momentum lacks a convincing argument for a comeback, with the company suffering a roughly 9% drawdown in the trailing month.</p>



<div class="wp-block-rank-math-toc-block" id="rank-math-toc"><h2>Table of Contents</h2><nav><ul><li><a href="#understanding-the-markov-chain-logic-for-abt-stock">Understanding the Markov Chain Logic for ABT Stock</a></li><li><a href="#quantifying-our-understanding-of-abbott-labs-stock">Quantifying Our Understanding of Abbott Labs Stock</a></li><li><a href="#why-face-value-probabilities-shouldnt-be-automatically-accepted">Why Face-Value Probabilities Shouldn’t be Automatically Accepted</a></li></ul></nav></div>



<p class="wp-block-paragraph">Still, from a contrarian view, now may be the opportune time to consider a long position in ABT stock. After all, if you wait on the sidelines until after Abbott Labs proves itself, the very act of proving itself will almost certainly swing the valuation northward. At that point, the conversation may shift toward whether or not the healthcare giant deserves its rich premium.</p>



<p class="wp-block-paragraph">Obviously, the key for speculative options traders is to bet that the wave will happen before it actually happens. You can’t wait for that confirmation because, for fear of being ridiculously tautological, confirmation undercuts the often-stratospheric risk-reward profile of speculation.</p>



<p class="wp-block-paragraph">In the case of Abbott Labs stock, however, the underlying company has been making a fool out of market participants (including yours truly). Technically, it would appear that ABT can’t decide whether it’s going to decisively move higher or lower. Instead, we’re stuck in a see-sawing action that only serves to universally frustrate traders on both sides of the sentiment aisle.</p>



<p class="wp-block-paragraph">Still, as someone focused on the data, options traders need to give ABT stock another look. Right now, the overwhelming consensus is that Abbott is locked in a bearish state. As such, this perception will likely alter the ticker’s probabilistic forward trajectory.</p>



<h2 id="understanding-the-markov-chain-logic-for-abt-stock" class="wp-block-heading">Understanding the Markov Chain Logic for ABT Stock</h2>



<p class="wp-block-paragraph">Let’s assume that each 10-week (rolling) sequence of Abbott Labs stock is a distinct behavioral state. Under this framework, we can easily label ABT as suffering a decisively bearish condition. That’s because out of the last 10 weekly candlesticks, only three of the sessions saw net positive price growth. That also means that within the defined period, 70% of the unit-wise volume incurred drawdowns.</p>



<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="600" height="247" data-source="article-image" src="https://cms.stocksearning.com/wp-content/uploads/2026/09/ABT-stock-distributions-600x247.png" alt="" class="wp-image-8390" srcset="https://cms.stocksearning.com/wp-content/uploads/2026/09/ABT-stock-distributions-600x247.png 600w, https://cms.stocksearning.com/wp-content/uploads/2026/09/ABT-stock-distributions-300x124.png 300w, https://cms.stocksearning.com/wp-content/uploads/2026/09/ABT-stock-distributions-768x317.png 768w, https://cms.stocksearning.com/wp-content/uploads/2026/09/ABT-stock-distributions-1536x633.png 1536w, https://cms.stocksearning.com/wp-content/uploads/2026/09/ABT-stock-distributions.png 1953w" sizes="auto, (max-width: 600px) 100vw, 600px" /></figure>



<p class="wp-block-paragraph">Why is this significant? First, this prolonged bearish state changes the current perception of ABT stock. Yes, as a whole, Abbott Laboratories enjoys prominence as a healthcare leader. But right now, investors aren’t treating ABT as a leader — more like a laggard. Second, because of this changed perception, it will likely alter how the market responds to Abbott moving forward.</p>



<p class="wp-block-paragraph">That’s basically the <a href="https://www.youtube.com/@MarkovSimulator" data-type="link" data-id="https://www.youtube.com/@MarkovSimulator" target="_blank" rel="noopener">architecture behind the Markov chain logic</a> that I use throughout my articles. Essentially, the future state depends on the current state.</p>



<p class="wp-block-paragraph">As an analogy, consider an old, used baseball bat. Would you pay $10,000 for it? No, that would be unreasonable. But what if you knew that the bat was signed by the legendary Babe Ruth? At that point, you’d be crazy not to make the purchase.</p>



<p class="wp-block-paragraph">What changed? Clearly, the bat remains a bat. So, the shift came in the perception of value — and what brought about the shift was the transition from one state to another. Previously, you saw a beat-up, old bat. Now, you see a beat-up, old bat that was signed by the Great Bambino.</p>



<p class="wp-block-paragraph">I would suggest to you that it’s the same principle when it comes to Abbott Laboratories stock. It is and remains an equity share of a healthcare juggernaut. But right now, the market cares less about the juggernaut status and more so that it lost roughly 9% in the past 30 days.</p>



<p class="wp-block-paragraph">As a basic presupposition, it’s reasonable to assume that the market will now treat ABT stock differently than if it were just cruising along, neither hot nor cold. Rather than just act on the presupposition itself — which would risk affirming the consequent — we can use data to justify a trading decision.</p>



<h2 id="quantifying-our-understanding-of-abbott-labs-stock" class="wp-block-heading">Quantifying Our Understanding of Abbott Labs Stock</h2>



<p class="wp-block-paragraph">Going back to the current behavioral state of ABT stock, we know that in the last 10 weeks, the ticker has only managed to print three up weeks. Quantitatively, we can label this particular sequence as 3-7-D: three up weeks, seven down weeks, downward slope across the total period.</p>



<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="600" height="330" data-source="article-image" src="https://cms.stocksearning.com/wp-content/uploads/2026/09/ABT-stock-markov-600x330.png" alt="abbott - StockEarnings" class="wp-image-8393" srcset="https://cms.stocksearning.com/wp-content/uploads/2026/09/ABT-stock-markov-600x330.png 600w, https://cms.stocksearning.com/wp-content/uploads/2026/09/ABT-stock-markov-300x165.png 300w, https://cms.stocksearning.com/wp-content/uploads/2026/09/ABT-stock-markov-768x422.png 768w, https://cms.stocksearning.com/wp-content/uploads/2026/09/ABT-stock-markov-1536x845.png 1536w, https://cms.stocksearning.com/wp-content/uploads/2026/09/ABT-stock-markov.png 1691w" sizes="auto, (max-width: 600px) 100vw, 600px" /></figure>



<p class="wp-block-paragraph">Looking at roughly the last five years (since January 2022), we know that this 3-7-D sequence has flashed 19 times on a rolling basis. Over the next 10 weeks, we can calculate that the median distribution tends to range between $95 and $116, with probability density hitting its peak at around $103.</p>



<p class="wp-block-paragraph">Another intriguing data point is that during the eighth week following the flashing of the aforementioned signal, Abbott Laboratories stock tends to shoot dramatically higher, enough so that there’s a 42.1% chance of ABT triggering the $110 price on the Nov. 20 expiration date.</p>



<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="600" height="368" data-source="article-image" src="https://cms.stocksearning.com/wp-content/uploads/2026/09/ABT-stock-odds-600x368.png" alt="abbott - StockEarnings" class="wp-image-8391" srcset="https://cms.stocksearning.com/wp-content/uploads/2026/09/ABT-stock-odds-600x368.png 600w, https://cms.stocksearning.com/wp-content/uploads/2026/09/ABT-stock-odds-300x184.png 300w, https://cms.stocksearning.com/wp-content/uploads/2026/09/ABT-stock-odds-768x471.png 768w, https://cms.stocksearning.com/wp-content/uploads/2026/09/ABT-stock-odds-1536x942.png 1536w, https://cms.stocksearning.com/wp-content/uploads/2026/09/ABT-stock-odds.png 1602w" sizes="auto, (max-width: 600px) 100vw, 600px" /></figure>



<p class="wp-block-paragraph">That’s significant intel because, as of this writing, the $110 level is the lowest second-leg strike price available on the November monthly options chain that provides an asymmetric payout (above 100%) for vertical spreads.</p>



<p class="wp-block-paragraph">Specifically, I’m looking at the <a href="https://www.youtube.com/watch?v=VnNvgcBo-ow" data-type="link" data-id="https://www.youtube.com/watch?v=VnNvgcBo-ow" target="_blank" rel="noopener">105/110 bull spread</a> (expiring Nov. 20) as a tempting proposition. Mechanically, a speculator would pay a net debit of $165 in the hopes that ABT stock rises and triggers the $110 strike on expiration. If it does, the maximum payout would be $335, a payout of 203%.</p>



<p class="wp-block-paragraph">That’s the type of idea you want to consider because you get back way more than you put in — provided that the spread works out as planned. That, of course, is the big question.</p>



<h2 id="why-face-value-probabilities-shouldnt-be-automatically-accepted" class="wp-block-heading">Why Face-Value Probabilities Shouldn’t be Automatically Accepted</h2>



<p class="wp-block-paragraph">At face value, the 105/110 bull spread has negative expected value (EV). That’s because the probability that ABT stock will actually hit $110 on expiration is <a href="https://optioncharts.io/options/ABT/probability-distribution?expiration_dates=2026-11-20%3Am&amp;option_type=all&amp;strike_range=all" target="_blank" rel="noopener">only 22.03%</a>. If you run an <a href="https://oddsjam.com/betting-calculators/expected-value" target="_blank" rel="noopener">EV calculation</a>, this trade, as it stands, suffers from a net payout value of -$54.86.</p>



<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="600" height="290" data-source="article-image" src="https://cms.stocksearning.com/wp-content/uploads/2026/09/ABT-stock-probability-distribution-600x290.png" alt="abbott - StockEarnings" class="wp-image-8392" srcset="https://cms.stocksearning.com/wp-content/uploads/2026/09/ABT-stock-probability-distribution-600x290.png 600w, https://cms.stocksearning.com/wp-content/uploads/2026/09/ABT-stock-probability-distribution-300x145.png 300w, https://cms.stocksearning.com/wp-content/uploads/2026/09/ABT-stock-probability-distribution-768x371.png 768w, https://cms.stocksearning.com/wp-content/uploads/2026/09/ABT-stock-probability-distribution-1536x742.png 1536w, https://cms.stocksearning.com/wp-content/uploads/2026/09/ABT-stock-probability-distribution.png 1804w" sizes="auto, (max-width: 600px) 100vw, 600px" /></figure>



<p class="wp-block-paragraph">That’s not good. But it might be drawing an inference from the wrong meta.</p>



<p class="wp-block-paragraph">Mathematically, the 22.03% figure is only true if we assume — as the underlying Black-Scholes model does — that ABT stock will undergo a random walk between now and the expiration date. However, a random walk is unlikely because of the current, bearish Markov state.</p>



<p class="wp-block-paragraph">Historically, at least over the trailing five years, when the 3-7-D sequence flashes, the median response tends to be contrarian and positive, enough so that the odds of hitting $110 stand at 42.1%, not 22.03%.</p>



<p class="wp-block-paragraph">When the Markov probability is integrated into the EV calculation, the trade would be expected to net +$45.48. And that’s the major difference between a random walk and a nonrandom one.</p>



<p class="wp-block-paragraph">No, we cannot change the payout structure — Wall Street is not in the business of handing out free money. What we can do, though, is to apply the appropriate presuppositional framework. This wouldn’t guarantee success as the options market remains incredibly risky. Still, in terms of relative risk, there’s a decent chance that ABT stock could be favorably mispriced.</p>



<p class="wp-block-paragraph"></p>
]]></content:encoded>
					
					<wfw:commentRss>https://cms.stocksearning.com/2026/10/abbott-labs-could-be-due-for-a-rally/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Beaten Up Abbott Laboratories (ABT) Could Be a Pre-Earnings Gift</title>
		<link>https://cms.stocksearning.com/2026/04/abt-could-be-a-pre-earnings-gift/</link>
					<comments>https://cms.stocksearning.com/2026/04/abt-could-be-a-pre-earnings-gift/#respond</comments>
		
		<dc:creator><![CDATA[Joshua Enomoto]]></dc:creator>
		<pubDate>Wed, 15 Apr 2026 12:00:00 +0000</pubDate>
				<category><![CDATA[Pre-Earnings]]></category>
		<category><![CDATA[ABT]]></category>
		<guid isPermaLink="false">https://cms.stocksearning.com/?p=1652</guid>

					<description><![CDATA[While there’s obvious skepticism surrounding ABT stock, the smart money is positioned to give the medical devices giant a chance.]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">Healthcare juggernaut <strong><a href="https://stocksearning.com/stocks/ABT/earnings-date">Abbott Laboratories (NYSE: ABT)</a></strong>, which specializes in medical devices, has not enjoyed an auspicious start to the new year. Since the beginning of January, ABT stock has fallen nearly 20%, an ignominious decline given its blue-chip status. It’s also problematic from a timing perspective, given how the company is about to release its fiscal <a href="https://www.abbottinvestor.com/events/event-details/q1-2026-abbott-earnings-conference-call" target="_blank" rel="noopener">first-quarter earnings this Thursday</a>.</p>



<div class="wp-block-rank-math-toc-block" id="rank-math-toc"><h2>Table of Contents</h2><nav><ul><li><a href="#volatility-skew-is-relatively-promising-for-abt-stock">Volatility Skew is Relatively Promising for ABT Stock</a></li><li><a href="#leveraging-inductive-analysis-to-trade-abbott-stock">Leveraging Inductive Analysis to Trade Abbott Stock</a></li><li><a href="#diving-into-the-details">Diving into the Details</a></li></ul></nav></div>



<p class="wp-block-paragraph">Analysts will be looking for earnings per share to hit $1.14 on revenue of $11.01 billion. While these metrics should be within realistic reach, Abbott hasn’t enjoyed a strong string of performances recently. In the <a href="https://stocksearning.com/stocks/ABT/historical-earnings-date">prior Q3 and Q4 reports</a>, the healthcare specialist merely met EPS targets, while missing on the top line.</p>



<p class="wp-block-paragraph">To be fair, it did beat on both profit and growth in Q2. Unfortunately, the impact has been limited, with ABT stock losing over 21% in the past 52 weeks. As such, options traders aren’t taking any chances. When you consider the positioning of trades in the derivatives market, the <a href="https://optioncharts.io/options/ABT/volatility-skew" target="_blank" rel="noopener">volatility skew</a> for the upcoming April 17 expiration date shows clear downside risk protection.</p>



<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="600" height="288" data-source="article-image" src="https://cms.stocksearning.com/wp-content/uploads/2026/04/ABT_1-002-600x288.png" alt="ABT - StockEarnings" class="wp-image-1664" srcset="https://cms.stocksearning.com/wp-content/uploads/2026/04/ABT_1-002-600x288.png 600w, https://cms.stocksearning.com/wp-content/uploads/2026/04/ABT_1-002-300x144.png 300w, https://cms.stocksearning.com/wp-content/uploads/2026/04/ABT_1-002-768x369.png 768w, https://cms.stocksearning.com/wp-content/uploads/2026/04/ABT_1-002.png 960w" sizes="auto, (max-width: 600px) 100vw, 600px" /></figure>



<p class="wp-block-paragraph">Again, no one should be surprised. Perusing the technical chart, the five-year look reveals a security that has plundered 19% of value. Obviously, that money could have been put to better use, imposing an air of regret on ABT stock.</p>



<p class="wp-block-paragraph">Still, for the aggressive contrarian, a deeper investigation may be warranted.</p>



<h2 class="wp-block-heading" id="volatility-skew-is-relatively-promising-for-abt-stock">Volatility Skew is Relatively Promising for ABT Stock</h2>



<p class="wp-block-paragraph">Let me get something straight from the get-go: the smart money is not necessarily prescient. Yes, the “smart” label implies a level of sophistication — and that assumption is generally warranted. However, there’s no indicator that absolutely reveals what top options traders are thinking. And even if such an indicator existed, following it wouldn’t automatically lead to profits.</p>



<p class="wp-block-paragraph">Nevertheless, options screeners like volatility skew provide important clues regarding sentiment. Further, I believe the skew is a more reliable mechanism for assessing sentiment — rather than, say, social media posts — because we’re dealing with professionals and institutional players.</p>



<p class="wp-block-paragraph">Simply put, these are the folks who have serious money. They can move the market if they want to. However, many of these elite traders choose to position themselves first in the options market to avoid triggering huge waves in the open arena. And that’s ultimately the signal provided by the volatility skew — we can see how much risk protection the smart money is willing to pay to have confidence in the trade.</p>



<p class="wp-block-paragraph">In the case of ABT stock, the skew for the April 17 expiration date shows relative calm near the current spot price. While it is true that there is urgency in the left side of the axis (thus indicating that the market is aggressively adjusting implied volatility per unit of distance from spot), the fact that such protection exists shouldn’t catch anyone by surprise. After all, we’re talking about a severely underperforming blue-chip stock.</p>



<p class="wp-block-paragraph">What is surprising, though, is the right side of the skew. Despite the prior carnage in Abbott stock and the lingering doubts, the smart money is clearly pricing for upside convexity. Stated differently, while they may fear further downside, these sophisticated traders recognize the potential for a near-term bounce back. Subsequently, they don’t want to be caught with at least some exposure to the bullish side of the trade.</p>



<p class="wp-block-paragraph">What’s more, the convexity is significantly elevated, even though the magnitude of urgency isn’t as strong as for downside mitigation. Suffering extensive red ink, the return of bullish sentiment will be a welcome sight for intrepid contrarians.</p>



<h2 class="wp-block-heading" id="leveraging-inductive-analysis-to-trade-abbott-stock">Leveraging Inductive Analysis to Trade Abbott Stock</h2>



<p class="wp-block-paragraph">When making any forecast about the future, induction is unavoidable. This term refers to a method of analysis that begins with specific observations to formulate a general rule or theory. Induction relies on the uniformity of nature or the assumption that the future will behave like the past.</p>



<p class="wp-block-paragraph">A simpler way to define the process is pattern recognition. By recording various events and tracking their evolution, we can postulate forward probabilities when those same events materialize in the present space. Although this is arguably the best mechanism for forecasting stock price movements, the methodology comes with a serious caveat.</p>



<p class="wp-block-paragraph">Basically, if you see a thousand white swans, it does not necessarily mean that all swans are white. Should the next swan be black, the presumed absoluteness of the inductive model would collapse immediately.</p>



<p class="wp-block-paragraph">As a result, market analysts never talk in absolutes. Because no one indicator or signal logically compels a security to act in a certain way, analysts use the language of probabilities, not certainties.</p>



<p class="wp-block-paragraph">While these caveats may sound problematic, induction is powerful because it conditions market behaviors on specific (discretized) events. In other words, we’re not looking at a smorgasbord of price action and forecasting next trades on vibes. Rather, we’re making specific observations and assigning probabilities of what may happen in the future based on these established markers.</p>



<h2 class="wp-block-heading" id="diving-into-the-details">Diving into the Details</h2>



<p class="wp-block-paragraph">Using data extending back to January 2019, we can observe that an average 10-week-long position generally features a tight distribution. Using the current ABT stock price as an anchor, a 10-week hold would be expected to range between $100 and $103.50.</p>



<p class="wp-block-paragraph">However, we’re conditioning Abbott stock under the current framework. In the past 10 weeks, ABT printed only three up weeks, leading to an overall downward slope. This 3-7-D sequence features a unique forward distribution relative to the aggregate condition of all sequences. Again, using the current spot as an anchor, we would expect ABT to land between $95 and $115 over the next 10 weeks.</p>



<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="600" height="246" data-source="article-image" src="https://cms.stocksearning.com/wp-content/uploads/2026/04/ABT-stock-fwd-distributions-600x246.png" alt="ABT - StockEarnings" class="wp-image-1653" srcset="https://cms.stocksearning.com/wp-content/uploads/2026/04/ABT-stock-fwd-distributions-600x246.png 600w, https://cms.stocksearning.com/wp-content/uploads/2026/04/ABT-stock-fwd-distributions-300x123.png 300w, https://cms.stocksearning.com/wp-content/uploads/2026/04/ABT-stock-fwd-distributions-768x315.png 768w, https://cms.stocksearning.com/wp-content/uploads/2026/04/ABT-stock-fwd-distributions.png 1195w" sizes="auto, (max-width: 600px) 100vw, 600px" /></figure>



<p class="wp-block-paragraph">Since this range stems from an inductive inference, I cannot say that ABT is logically compelled to land in this distribution. However, if you want to get extremely aggressive, you may consider the 105/110 bull call spread expiring June 18.</p>



<p class="wp-block-paragraph">Should ABT stock rise through the $110 strike at expiration, the maximum (capped) payout would clock in at nearly 186%. That would turn a $175 net debit into a $325 profit. Further, the second-leg strike is within the observed forward distribution of ABT under 3-7-D conditions.</p>



<p class="wp-block-paragraph">If you want to dip your toes into true contrarianism, Abbott should be on your radar.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://cms.stocksearning.com/2026/04/abt-could-be-a-pre-earnings-gift/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>5 Crushed Stocks That Insiders are Buying</title>
		<link>https://cms.stocksearning.com/2026/01/5-crushed-stocks-with-insider-buying/</link>
					<comments>https://cms.stocksearning.com/2026/01/5-crushed-stocks-with-insider-buying/#respond</comments>
		
		<dc:creator><![CDATA[Ian Cooper]]></dc:creator>
		<pubDate>Thu, 29 Jan 2026 12:00:00 +0000</pubDate>
				<category><![CDATA[Evergreen]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BBWI]]></category>
		<category><![CDATA[ELAN]]></category>
		<category><![CDATA[FISV]]></category>
		<category><![CDATA[gme]]></category>
		<guid isPermaLink="false">https://cms.stocksearning.com/?p=988</guid>

					<description><![CDATA[Buying low and selling high sounds easy to do. But what happens when you&#8217;re dealing with crushed stocks? This isn&#8217;t just about stocks that are underperforming the market. I&#8217;m talking about stocks that are down so much, you&#8217;re questioning the reason you bought in in the first place. Let me be clear, sometimes crushed stocks [&#8230;]]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">Buying low and selling high sounds easy to do. But what happens when you&#8217;re dealing with crushed stocks? This isn&#8217;t just about stocks that are underperforming the market. I&#8217;m talking about stocks that are down so much, you&#8217;re questioning the reason you bought in in the first place. </p>



<div class="wp-block-rank-math-toc-block" id="rank-math-toc"><h2>Table of Contents</h2><nav><ul><li><a href="#crushed-stocks-1-abbott-laboratories">Crushed Stocks #1: Abbott Laboratories</a></li><li><a href="#crushed-stocks-2-game-stop">Crushed Stocks #2: GameStop</a></li><li><a href="#crushed-stocks-3-elanco-animal-health">Crushed Stocks #3: Elanco Animal Health</a></li><li><a href="#crushed-stocks-4-bath-body-works">Crushed Stocks #4: Bath &amp; Body Works</a></li><li><a href="#crushed-stocks-5-fiserv">Crushed Stocks #5: Fiserv</a></li><li><a href="#final-thoughts-on-insider-buying">Final Thoughts on Insider Buying</a></li></ul></nav></div>



<p class="wp-block-paragraph">Let me be clear, sometimes crushed stocks deserve to be crushed. In many cases, something fundamental or structural has changed the thesis for owning the stock. </p>



<p class="wp-block-paragraph">However, sometimes selling momentum gets overdone. When that happens, it&#8217;s usually the company insiders who are the first to know. </p>



<p class="wp-block-paragraph">That&#8217;s why you should always keep an eye on insider buying. After all, if insiders are putting their money where their mouths are, it’s a sign of confidence.</p>



<h2 class="wp-block-heading" id="crushed-stocks-1-abbott-laboratories">Crushed Stocks #1: Abbott Laboratories</h2>



<p class="wp-block-paragraph"><a href="https://www.stocksearning.com//stocks/ABT/earnings-date">Abbott Laboratories (NYSE: ABT)</a> is down about 16.6% in 2026. However, almost all of that loss came after the company&#8217;s <a href="https://files.quartr.com/conference-calls/f49f6-2026-01-22-01-15-35.pdf?ref=TWFya2V0QmVhdCBNZWRpYSBMTEM=" target="_blank" rel="noopener">fourth-quarter earnings report</a> on Jan. 22. The stock was crushed following the report. In fact, it had its worst showing in more than 20 years, gapping from about $120 to $105.60.&nbsp;&nbsp;</p>



<p class="wp-block-paragraph">This was despite the fact that the company’s adjusted earnings beat analysts’ forecasts by a penny. However, sales came to $11.5 billion, missing the $11.8 billion estimate. </p>



<p class="wp-block-paragraph">The sell-off made the report look like a disaster.&nbsp;&nbsp;However, for Chairman and CEO Robert Ford, it was an opportunity. After the drop, he reportedly bought 18,800 shares of ABT for just over $2 million on January 23.</p>



<p class="wp-block-paragraph">Despite the earnings mess, Ford said Abbott was well-positioned to accelerate growth in 2026. “While we know we’ve got some work to do in nutrition, I can guarantee you that we’re not distracted by that,” he added, as quoted by Barron’s.</p>



<h2 class="wp-block-heading" id="crushed-stocks-2-game-stop">Crushed Stocks #2: GameStop</h2>



<p class="wp-block-paragraph"><strong><a href="https://www.stocksearning.com//stocks/GME/earnings-date">GameStop Corp. (NYSE: GME)</a></strong> was one of the original meme stocks, and it&#8217;s never shaken that reputation. To be fair, the company and its loyal band of retail investors have leaned into the reputation. </p>



<p class="wp-block-paragraph">The company is trying to make a pivot from being a retail dinosaur to being a digital-first gaming and entertainment company. This has included speculation in Bitcoin and forays into seemingly unrelated businesses to manufacture a new equity story.  </p>



<p class="wp-block-paragraph">GME stock is down more than 51% in the last five years. But it&#8217;s showing big signs of life in 2026. That&#8217;s caused CEO Ryan Cohen to buy 500,000 shares for about $21.12 each for nearly $21.4 million.&nbsp;</p>



<p class="wp-block-paragraph">He wasn&#8217;t alone. Board member Alain Attal picked up 12,000 shares for about $20.90 each.&nbsp;Even investor Michael Burry disclosed a long position in GME, noting that he likes the company’s untapped value and strategic optionality under Ryan Cohen.&nbsp;&nbsp;</p>



<p class="wp-block-paragraph">As noted by Seeking Alpha, “Burry framed GameStop not as a typical retail business, but as a cash-generating platform with a young, disciplined leadership team and the optionality to deploy billions in a patient, intelligent manner.”</p>



<h2 class="wp-block-heading" id="crushed-stocks-3-elanco-animal-health">Crushed Stocks #3: Elanco Animal Health</h2>



<p class="wp-block-paragraph">Since bottoming out in April at around $8 a share, <strong><a href="https://www.stocksearning.com//stocks/ELAN/earnings-date">Elanco Animal Health Inc. (NYSE: ELAN)</a></strong> stock is now up to $24 and could rally even higher.&nbsp;&nbsp;Most recently, CEO Jeffrey Simmons paid $478,500 to buy 22,000 shares on December 11 at an average price of $21.75 a share. </p>



<p class="wp-block-paragraph">The company, which was spun off from Eli Lilly in 2018, has been explosive thanks to key product launches, including chewable parasite preventative for dogs, as well as anti-itch medication.</p>



<p class="wp-block-paragraph">Americans spend big money on their pets. In 2024, the average household spent about $40 billion on vet care and pet medications alone.&nbsp;By 2027, spending is expected to soar to $173 billion, as noted by Fortune.&nbsp;Americans will spend a total of&nbsp;$157 billion&nbsp;on their pets by the end of 2025; according to projections, U.S. pet spending will total almost&nbsp;<em>$200 billion</em>&nbsp;in 2030, as noted by Capital One Spending.</p>



<p class="wp-block-paragraph">Those are substantial catalysts for pet companies like ELAN.</p>



<h2 class="wp-block-heading" id="crushed-stocks-4-bath-body-works">Crushed Stocks #4: Bath &amp; Body Works</h2>



<p class="wp-block-paragraph"><strong><a href="https://www.stocksearning.com//stocks/BBWI/earnings-date">Bath &amp; Body Works (NYSE: BBWI)</a></strong> hasn&#8217;t had a great year. Since the start of 2025, BBWI fell from about $40 to $14.28. It&#8217;s now back to $21.65, and showing some signs of life again after tanking on earnings.</p>



<p class="wp-block-paragraph">But before the recent rally, insiders were buying.&nbsp;</p>



<p class="wp-block-paragraph">On November 21, director Lucy Brady bought just over 3,469 shares for $14.40 a share. Huntington Bancshares CEO Stephen Steinour bought 6,700 shares for $14.86 per share. Former Mastercard executive Francis Hondal bought 3,343 shares for about $15 per share. Hershey VP and CFO Steven Voskuil bought 20,000 shares for about $15.04 per share.&nbsp;</p>



<p class="wp-block-paragraph">On November 24, Board Chair Sarah Nash picked up 10,000 shares for $15.58 per share. Signet Jewelers’ CEO James Symancyk bought 22,500 shares for about $15.58 per share.</p>



<h2 class="wp-block-heading" id="crushed-stocks-5-fiserv">Crushed Stocks #5: Fiserv</h2>



<p class="wp-block-paragraph"><strong><a href="https://www.stocksearning.com//stocks/FISV/earnings-date">Fiserv Inc. (NASDAQ: FISV)</a></strong> operates in the emerging financial technology (fintech) space. But that hasn&#8217;t meant much to investors. Just weeks ago, FISV stock gapped from about $130 to a recent low of about $60.&nbsp;</p>



<p class="wp-block-paragraph">However, several company insiders have had enough. CFO Paul Todd just bought 17,000 shares for $1 million. Chief Administrative and Legal Officer Adam Rosman just bought 7,900 shares for $499,201.</p>



<p class="wp-block-paragraph">This was after the stock was sent screaming lower after the company cut its growth forecast and earnings outlook. The company also said its operations in Argentina would be hurt by poor economic conditions, which forced the stock below $100 for the first time since 2003, as noted by Barron’s.</p>



<h2 class="wp-block-heading" id="final-thoughts-on-insider-buying">Final Thoughts on Insider Buying</h2>



<p class="wp-block-paragraph">There are many reasons why insiders will sell a stock. For many executives, stock options are an integral part of their compensation. These sales are usually orchestrated well in advance and without regard to the stock&#8217;s current price.</p>



<p class="wp-block-paragraph">However, insiders are only buying for one reason. That is, they believe the stock is undervalued. If you&#8217;re looking for crushed stocks with comeback potential, these five stocks may be a good place to start. </p>



<p class="wp-block-paragraph"></p>
]]></content:encoded>
					
					<wfw:commentRss>https://cms.stocksearning.com/2026/01/5-crushed-stocks-with-insider-buying/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
	</channel>
</rss>
